33 reports

  • GLOBAL ANTIVIRAL DRUGS MARKET SEGMENTATION BY THERAPIES
  • VIRAL DISEASE

GLOBAL HIV/ AIDS THERAPEUTICS MARKET HIV IS ONE OF THE MOST WIDESPREAD VIRAL DISORDERS THROUGHOUT THE WORLD.

  • Influenza
  • Bristol-Myers Squibb Company
  • Gilead Sciences, Inc.
  • GlaxoSmithKline plc
  • ViiV Healthcare Ltd.

HUMAN IMMUNODEFICIENCY VIRUS (HIV): COMPETITIVE LANDSCAPE TO 2026, FEBRUARY 2018, GDHC##CL.

  • Influenza
  • United States
  • Roche Group
  • Sanofi S.A.
  • Shionogi & Co., Ltd.

PRIOR TO JOINING GLOBALDATA, NATASHA WORKED AS AN EPIDEMIOLOGIST FOR THREE YEARS IN THE HIV/ AIDS SURVEILLANCE PROGRAM AT THE MASSACHUSETTS DEPARTMENT OF PUBLIC HEALTH (MDPH).

  • Influenza
  • Market Size
  • CSL Limited
  • Daiichi Sankyo Company
  • Mitsubishi Corporation
  • 22.1 MALTA SEASONAL INFLUENZA VACCINATED TOTAL POPULATION

In Malta, seasonal influenza vaccination is recommended for all aged ## years and over, children between ## months and ## months old, and persons of any age suffering from chronic diseases of the lungs, heart, liver, kidney, diabetes, and any immunodeficiency conditions, including HIV and

  • Influenza
  • Vaccine
  • Northern Europe
  • Forecast
  • Market Size
  • Which factors contribute to the severity of seasonal influenza?

Young children and the elderly are the most at risk of severe and/ or fatal influenza, as well as consumers with underlying health conditions, such as heart disease or HIV/ AIDS.

  • Influenza
  • Vaccine
  • United States
  • Demand
  • Mondelez International, Inc.
  • 6.1 Malta Seasonal Influenza Vaccinated Total Population

In Malta, seasonal influenza vaccination is recommended for all aged ## years and over, children between ## months and ## months old, and persons of any age suffering from chronic diseases of the lungs, heart, liver, kidney, diabetes, and any immunodeficiency conditions, including HIV and

  • Influenza
  • Vaccine
  • Southern Europe
  • Forecast
  • Market Size
  • 21.1 MALTA SEASONAL INFLUENZA VACCINATED TOTAL POPULATION

In Malta, seasonal influenza vaccination is recommended for all aged ## years and over, children between ## months and ## months old, and persons of any age suffering from chronic diseases of the lungs, heart, liver, kidney, diabetes, and any immunodeficiency conditions, including HIV and

  • Influenza
  • Vaccine
  • Northern Europe
  • Forecast
  • Market Size

Prior to joining GlobalData, Natasha worked as an epidemiologist for three years in the HIV/ AIDS Surveillance Program at the Massachusetts Department of Public Health (MDPH).

  • Influenza
  • Germany
  • Japan
  • United States
  • Forecast
  • PRODUCTS UNDER DEVELOPMENT BY COMPANIES, H2 2018
  • NUMBER OF PRODUCTS UNDER DEVELOPMENT BY INDICATIONS, H2 2018

It was also under development for infections due to H##N##, HIV.

  • Influenza
  • Pharmaceutical
  • United States
  • World
  • Hemispherx Biopharma, Inc.
  • NVINF-2 - DRUG PROFILE

It offers pipeline product portfolio such as drugs for various indications such as HIV, influenza, flaviviruses including dengue and eye drops, among others.

  • Influenza
  • United States
  • World
  • Product Initiative
  • BiondVax Pharmaceuticals Ltd.
  • NVINF-2 - DRUG PROFILE

It offers pipeline product portfolio such as drugs for various indications such as HIV, influenza, flaviviruses including dengue and eye drops, among others.

  • Influenza
  • Vaccine
  • United States
  • Company Operations
  • NanoViricides, Inc.
  • NVINF-2 - DRUG PROFILE

It offers pipeline product portfolio such as drugs for various indications such as HIV, influenza, flaviviruses including dengue and eye drops, among others.

  • Influenza
  • United States
  • Company
  • Product Initiative
  • NanoViricides, Inc.
  • NVINF-2 - DRUG PROFILE

The drug candidate is in Phase-II stage of development for pancreatic cancer in China and U. S and Phase II stage of development for ovarian cancer, hepatocellular carcinoma and HIV/ AIDS and head and neck cancer.

  • Influenza
  • Therapy
  • Vaccine
  • United States
  • Product Initiative
  • NVINF-2 - DRUG PROFILE

It offers pipeline product portfolio such as drugs for various indications such as HIV, influenza, flaviviruses including dengue and eye drops, among others.

  • Influenza
  • Pathology
  • Vaccine
  • United States
  • Product Initiative

The institute' s research areas include infectious diseases such as tuberculosis and influenza, HIV/ AIDS, biodefense; and immune-mediated diseases including asthma and allergy.

  • Influenza
  • Europe
  • Israel
  • United States
  • BiondVax Pharmaceuticals Ltd.

GOVERNMENT S INITIATIVE TO DELIVER LIFE-SAVING SERVICES AND IMPROVE THE LIVES OF THOSE LIVING WITH HIV/ AIDS AROUND THE WORLD.

  • Clinical Trial
  • Influenza
  • Interventional Cardiology Device
  • Medical Device
  • Endologix, Inc.
  • 5. ALL THE TRIALS INCLUDED ARE UNIQUE TRIALS.

THE PROMINENT FEATURES OF THIS REPORT ARE - ##.

  • Clinical Trial
  • Influenza
  • World
  • Product Initiative
  • GlaxoSmithKline plc
  • 5. All the trials included are unique trials.

HIV [strains C## + TV##] (bivalent) vaccine Total Source: GlobalData' s Pharma Intelligence Center Clinical Trials Database (*)Trials are taken for a time period of 1995 - 2018 2018 trials are taken as of November 2018 ## ## ## ## ## ## ## CLINICAL TRIAL PROFILE SN

  • Clinical Trial
  • Influenza
  • Pharmaceutical
  • World
  • Product Initiative
  • NVINF-2 - DRUG PROFILE

Drug Name Company/ Institute Name Licensed From Company Development Partner Product Description NA NA SYNTHETIC PEPTIDES FOR INFLUENZA, HSV AND HIV INFECTIONS - DRUG PROFILE SYNTHETIC PEPTIDES FOR INFLUENZA, HSV AND HIV INFECTIONS UNIVERSITY OF WISCONSIN MADISON SYNTHETIC PEPTI

  • Influenza
  • Vaccine
  • United States
  • Product Initiative
  • BiondVax Pharmaceuticals Ltd.
  • NVINF-2 - DRUG PROFILE

Drug Name Company/ Institute Name Licensed From Company Development Partner Product Description NA NA SYNTHETIC PEPTIDES FOR INFLUENZA, HSV AND HIV INFECTIONS - DRUG PROFILE SYNTHETIC PEPTIDES FOR INFLUENZA, HSV AND HIV INFECTIONS UNIVERSITY OF WISCONSIN MADISON SYNTHETIC PEPTI

  • Influenza
  • Monoclonal Antibody
  • Vaccine
  • United States
  • BiondVax Pharmaceuticals Ltd.
  • 5. ALL THE TRIALS INCLUDED ARE UNIQUE TRIALS.

Hoffmann-La Roche Ltd Microgen Scientific Industrial Company for Immunobiological ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## Medicines ## ## ## ## ## ## ## ## Altimmune Inc ## ## ## ## ## ## ## ## CSL Ltd Source: GlobalData' s Pharma Intelligence Center C

  • Drug Development
  • Influenza
  • World
  • Product Initiative
  • GlaxoSmithKline plc
  • CLINICAL TRIAL PROFILE SNAPSHOTS

THE PROMINENT FEATURES OF THIS REPORT ARE - ##.

  • Clinical Trial
  • Influenza
  • Therapy
  • World
  • Product Initiative
  • NVINF-2 - DRUG PROFILE

THE DRUG CANDIDATE IS IN PHASE-II STAGE OF DEVELOPMENT FOR PANCREATIC CANCER IN CHINA AND U. S AND PHASE II STAGE OF DEVELOPMENT FOR OVARIAN CANCER, HEPATOCELLULAR CARCINOMA AND HIV/ AIDS AND HEAD AND NECK CANCER.

  • Influenza
  • Therapy
  • Vaccine
  • United States
  • Product Initiative

THE PROMINENT FEATURES OF THIS REPORT ARE - ##.

  • Infectious Disease
  • Influenza
  • World
  • Product Initiative
  • GlaxoSmithKline plc
  • May 02, 2018: Scripps Research team receives $12 million grant to improve flu and malaria vaccines

Ward is also affiliated with the International AIDS Vaccine Initiative (IAVI) Neutralizing Antibody Center and Center for HIV/ AIDS Vaccine Immunology and Immunogen Discovery (CHAVI-ID) at Scripps Research.

  • Infectious Disease
  • Influenza
  • Pharmaceutical
  • Therapy
  • Vaccine

RISK FACTORS INCLUDE ASTHMA, NASAL PASSAGE ABNORMALITY, IMMUNE SYSTEM DISORDER, SUCH AS HIV/ AIDS OR CYSTIC FIBROSIS AND ANOTHER ALLERGIC CONDITION.

  • Cough And Cold
  • Influenza
  • Therapy
  • United States
  • Product Initiative
  • Daiichi Sankyo Company, Limited - Dormant Developmental Projects,2016

THE DRUG CANDIDATE BY INHIBITING THE DR## ACTIVITY AIDS IN THE TREATMENT OF UNDERLYING CAUSE.

  • Cancer
  • Influenza
  • Monoclonal Antibody
  • Therapy
  • Daiichi Sankyo Company

It was also under development for the treatment of melanoma, renal cell carcinoma and HIV / AIDS.

  • Influenza
  • Monoclonal Antibody
  • Vaccine
  • United States
  • Hemispherx Biopharma, Inc.
  • Clinical Trial Profile Snapshots

The prominent features of this report are - ##.

  • Clinical Trial
  • Influenza
  • Vaccine
  • World
  • Product Initiative
  • EPIVAX, INC. - RESEARCH AND DEVELOPMENT OVERVIEW

Research and Development Brief Discovery/ Preclinical Trial Details The company reported a study where HIV-## T cell epitopes were evaluated for HLA binding and immunogenicity with PBMCs from HIV-infected patients.

  • Influenza
  • Medical Biotechnology
  • Vaccine
  • United States
  • EpiVax, Inc.